Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline
Open Access
- 1 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 34 (5), 663-675
- https://doi.org/10.1007/s10557-020-07030-9
Abstract
Purpose The ischemic/bleeding trade-off of continuing dual antiplatelet therapy (DAPT) beyond 1 year after PCI for patients with high thrombotic risk (HTR) as endorsed by 2018 ESC/EACTS myocardial revascularization guidelines remain unknown. Methods Patients undergoing coronary stenting between January 2013 and December 2013 from the prospective Fuwai registry were defined as HTR if they met at least 1 ESC/EACTS guideline-endorsed HTR criteria. A total of 4578 patients who were at HTR and were events free at 1 year after the index procedure were evaluated. The primary efficacy outcome was major adverse cardiac and cerebrovascular events (MACCE) (composite of all-cause death, myocardial infarction, or stroke). Results Median follow-up period was 2.4 years. > 1-year DAPT with clopidogrel and aspirin significantly reduced the risk of MACCE compared with <= 1-year DAPT (1.9% vs. 4.6%; hazard ratio (HR): 0.38; 95% confidence interval (CI): 0.27-0.54;P < 0.001), driven by a reduction in all-cause death (0.2% vs. 3.0%; HR, 0.07; 95% CI, 0.03-0.15). Cardiac death and definite/probable stent thrombosis also occurred less frequently in prolonged DAPT group. Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurred similarly between both groups (1.1% vs. 0.9%; HR, 1.11; 95% CI, 0.58-2.13;P = 0.763). Similar results were found using multivariable Cox model, propensity score-matched, and inverse probability of treatment weighting analysis. Conclusions Among patients with ESC-endorsed HTR who were free from major ischemic or bleeding events 1 year after coronary stenting, continued DAPT beyond 1 year might offer better effectiveness in terms of atherothrombotic events and comparable safety in terms of clinically relevant bleeding compared with <= 1-year DAPT. ESC-HTR criteria is an important parameter to take into account in tailoring DAPT prolongation.Funding Information
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-1-009)
- National Natural Science Foundation of China (81870277)
- National Key Research and Development Program of China (2018YFC1315602)
- The capital health research and development of special (2020-1-4032)
This publication has 52 references indexed in Scilit:
- Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyThe Lancet, 2013
- Prolonged Clopidogrel Use After Bare Metal and Drug-Eluting Stent PlacementCirculation: Cardiovascular Interventions, 2012
- Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting StentsCirculation, 2012
- A Prospective Natural-History Study of Coronary AtherosclerosisThe New England Journal of Medicine, 2011
- Stenting of complex lesions: an overviewNature Reviews Cardiology, 2010
- The Relationship and Threshold of Stent Length With Regard to Risk of Stent Thrombosis After Drug-Eluting Stent ImplantationJACC: Cardiovascular Interventions, 2010
- Pathological Correlates of Late Drug-Eluting Stent ThrombosisCirculation, 2007
- Beyond RestenosisCirculation, 2004
- Platelet Function in Acute Myocardial Infarction Treated With Direct AngioplastyCirculation, 1996
- Platelet Hyperreactivity and Prognosis in Survivors of Myocardial InfarctionThe New England Journal of Medicine, 1990